Longeveron Inc. (LGVN) stock
LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.92−0.19 (-9.00%)
Close on Nov 18, 2026Market cap $61.21MP/E –Yield –
Longeveron gross margin
Gross margin is gross profit as a percentage of revenue.
Longeveron's gross margin for the twelve months ending Jun 30, 2026 was 69.8%. For fiscal 2025 it was 67.0%, against 78.8% the year before. The highest annual figure on record is 78.8% in fiscal 2024.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 67.0% | −11.8 |
| FY2024 | Dec 31, 2024 | 78.8% | +47.6 |
| FY2023 | Dec 31, 2023 | 31.2% | −9.5 |
| FY2022 | Dec 31, 2022 | 40.7% | −4.5 |
| FY2021 | Dec 31, 2021 | 45.2% | +12.7 |
| FY2020 | Dec 31, 2020 | 32.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 63.4% | +17.2 |
| Q1 FY2026 | Mar 31, 2026 | 66.3% | −5.8 |
| Q4 FY2025 | Dec 31, 2025 | 70.4% | −17.5 |
| Q3 FY2025 | Sep 30, 2025 | 91.2% | +3.0 |
| Q2 FY2025 | Jun 30, 2025 | 46.2% | −27.3 |
| Q1 FY2025 | Mar 31, 2025 | 72.2% | +12.1 |
| Q4 FY2024 | Dec 31, 2024 | 87.9% | +91.1 |
| Q3 FY2024 | Sep 30, 2024 | 88.2% | +52.2 |
| Q2 FY2024 | Jun 30, 2024 | 73.5% | +30.6 |
| Q1 FY2024 | Mar 31, 2024 | 60.0% | +32.8 |
| Q4 FY2023 | Dec 31, 2023 | -3.2% | −37.5 |
| Q3 FY2023 | Sep 30, 2023 | 36.0% | −8.6 |
| Q2 FY2023 | Jun 30, 2023 | 42.9% | +9.8 |
| Q1 FY2023 | Mar 31, 2023 | 27.2% | −43.4 |
| Q2 FY2022 | Jun 30, 2022 | 34.3% | −8.2 |
| Q1 FY2022 | Mar 31, 2022 | 44.6% | +5.0 |
| Q4 FY2021 | Dec 31, 2021 | 33.0% | −11.8 |
| Q3 FY2021 | Sep 30, 2021 | 70.7% | +50.7 |
| Q2 FY2021 | Jun 30, 2021 | 42.5% | +29.8 |
| Q1 FY2021 | Mar 31, 2021 | 39.6% | −7.9 |
| Q4 FY2020 | Dec 31, 2020 | 44.8% | – |
| Q3 FY2020 | Sep 30, 2020 | 20.0% | – |
| Q2 FY2020 | Jun 30, 2020 | 12.8% | – |
| Q1 FY2020 | Mar 31, 2020 | 47.5% | – |
See a number that looks wrong?